Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19251906 | ANTI-CD79B PROTEIN MONOCLONAL ANTIBODY, PRODUCTS CONTAINING THE SAME, AND USES THEREOF | June 2025 | September 2025 | Allow | 3 | 0 | 0 | No | No |
| 17636923 | AMYLOID-BETA ANTIBODIES | February 2022 | February 2026 | Allow | 48 | 1 | 0 | No | No |
| 17665057 | BLOOD INDICATORS OF ALZHEIMER'S DISEASE | February 2022 | December 2025 | Allow | 46 | 2 | 0 | Yes | No |
| 17227296 | METHOD OF USING A CHLOROGENIC ACID COMPOSITION FOR SUPPORTING COGNITIVE FUNCTION | April 2021 | December 2024 | Allow | 44 | 2 | 0 | No | No |
| 17264140 | INTERFERON-GAMMA BIASED AGONISTS | January 2021 | May 2025 | Allow | 51 | 1 | 1 | Yes | No |
| 17251059 | Treatment of Placental Chronic Histiocytic Intervillositis Using an Inhibitor of Interleukin-1 | December 2020 | May 2025 | Abandon | 53 | 1 | 1 | No | No |
| 17113600 | HUMAN ISLET AMYLOID POLYPEPTIDE (HIAPP) SPECIFIC ANTIBODIES AND USES THEREOF | December 2020 | March 2026 | Abandon | 60 | 0 | 1 | No | No |
| 17105858 | BIPARTITE MOLECULES AND USES THEREOF IN TREATING DISEASES ASSOCIATED WITH ABNORMAL PROTEIN AGGREGATES | November 2020 | December 2025 | Allow | 60 | 1 | 0 | No | No |
| 17061918 | ANTI-CONNEXIN ANTIBODY FORMULATIONS | October 2020 | March 2025 | Allow | 53 | 1 | 1 | Yes | No |
| 17043510 | MONOCLONAL ANTIBODY SPECIFICALLY REACTING WITH DUPAN-2 ANTIGEN AND METHOD FOR PRODUCING SAME | September 2020 | October 2025 | Abandon | 60 | 2 | 1 | Yes | No |
| 17014425 | N-TERMINAL EPITOPES IN AMYLOID BETA AND CONFORMATIONALLY-SELECTIVE ANTIBODIES THERETO | September 2020 | August 2024 | Allow | 47 | 3 | 1 | Yes | No |
| 16971157 | ALPHA-SYNUCLEIN SINGLE DOMAIN ANTIBODIES | August 2020 | July 2024 | Allow | 47 | 1 | 1 | Yes | No |
| 16940263 | PEPTIDE VACCINE FOR PREVENTION AND IMMUNOTHERAPY OF DEMENTIA OF THE ALZHEIMER'S TYPE | July 2020 | October 2025 | Allow | 60 | 5 | 1 | No | No |
| 16936457 | DOSING REGIMES FOR TREATMENT OF SYNUCLEINOPATHIES | July 2020 | December 2025 | Allow | 60 | 5 | 1 | No | No |
| 16925664 | METHODS AND COMPOSITIONS COMPRISING REDUCED LEVEL OF HOST CELL PROTEINS | July 2020 | August 2025 | Abandon | 60 | 3 | 1 | No | No |
| 16959013 | DEAD ANTIGEN STIMULATED IMMATURE HETEROGENOUS DENDRITIC CELLS AS THERAPEUTICS FOR DISEASES | June 2020 | May 2024 | Abandon | 46 | 1 | 1 | No | No |
| 16646536 | ANTI-TREM2 ANTIBODIES AND METHODS OF USE THEREOF | March 2020 | September 2025 | Abandon | 60 | 4 | 1 | No | No |
| 16698193 | Methods for Treating Lipid-Related Diseases Including Xanthomas, Carotid Artery Stenoses, and Cerebral Atherosclerosis | November 2019 | August 2022 | Abandon | 33 | 3 | 1 | No | No |
| 16693783 | PEPTIDE ANALYZING METHOD | November 2019 | February 2026 | Allow | 60 | 7 | 0 | No | No |
| 16409543 | Methods for Prophylactically Preventing, Slowing the Progression of, or Treating Cerebral Amyloid Angiopathy, Alzheimer's Disease and/or Acute Stroke | May 2019 | October 2022 | Abandon | 41 | 4 | 0 | No | No |
| 16220788 | Methods, Antibodies, and Vaccines Utilizing Epitopes of Alpha Synuclein for Treatment of Parkinson's Disease | December 2018 | January 2020 | Allow | 13 | 2 | 0 | No | No |
| 15909765 | Methods for Prophylactically Preventing, Slowing the Progression of, or Treating Alzheimer's Disease | March 2018 | January 2023 | Abandon | 58 | 5 | 0 | No | No |
| 15876808 | Methods for Treating Cholesterol-Related Diseases | January 2018 | April 2023 | Abandon | 60 | 6 | 0 | Yes | No |
| 15559078 | SPECIFIC AMYLOID BETA BINDING PEPTIDES AND THE USE OF SAME FOR TREATING AND DIAGNOSING ALZHEIMER'S DEMENTIA | September 2017 | November 2018 | Allow | 14 | 1 | 1 | Yes | No |
| 15549725 | Specific A-beta Species-Binding Peptides for the Therapy and/or Diagnosis of Alzheimer's Dementia | August 2017 | September 2018 | Allow | 13 | 1 | 1 | No | No |
| 15528204 | PEPTIDES | May 2017 | October 2018 | Allow | 17 | 1 | 1 | Yes | No |
| 15503027 | COMBINATION ALZHEIMER THERAPY USING ANTI-N3PGLU ABETA ANTIBODIES + A BACE INHIBITOR | February 2017 | March 2018 | Allow | 13 | 1 | 0 | Yes | No |
| 15300974 | METHODS, COMPOSITIONS, DIAGNOSTICS AND ASSAYS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | September 2016 | October 2018 | Allow | 25 | 1 | 1 | Yes | No |
| 15124216 | MITOCHONDRIAL PREPROTEINS AS MARKERS FOR ALZHEIMER'S DISEASE | September 2016 | July 2019 | Allow | 34 | 3 | 1 | Yes | No |
| 15205649 | Prion Protein Antibodies For The Treatment Of Alzheimer's Disease | July 2016 | January 2019 | Allow | 31 | 3 | 0 | Yes | No |
| 15171708 | HUMANIZED ANTIBODIES SPECIFIC TO THE PROTOFIBRILLAR FORM OF THE BETA-AMYLOID PEPTIDE | June 2016 | June 2018 | Allow | 25 | 2 | 0 | Yes | No |
| 15098210 | FUSION PROTEINS FOR USE AS IMMUNOGENIC ENHANCERS FOR INDUCING ANTIGEN-SPECIFIC T CELL RESPONSES | April 2016 | April 2017 | Allow | 12 | 1 | 0 | No | No |
| 14910172 | An Antibody Therapy for Amyloid Beta Disease | February 2016 | October 2017 | Allow | 20 | 1 | 0 | Yes | No |
| 14884542 | ANTI-ALPHA-SYNUCLEIN ANTIBODIES AND METHODS OF USE | October 2015 | April 2017 | Allow | 18 | 1 | 1 | Yes | No |
| 14747716 | Compositions Comprising Receptor-Associated Protein (RAP) Variants Specific for CR-Containing Proteins and Uses Thereof | June 2015 | September 2017 | Allow | 27 | 2 | 1 | Yes | No |
| 14407724 | ANTIBODIES AND CONJUGATES THAT TARGET MISFOLDED PRION PROTEIN | December 2014 | November 2015 | Allow | 11 | 0 | 0 | Yes | No |
| 14095947 | FUSION PROTEINS FOR USE AS IMMUNOGENIC ENHANCERS FOR INDUCING ANTIGEN-SPECIFIC T CELL RESPONSES | December 2013 | January 2016 | Allow | 26 | 1 | 0 | Yes | No |
| 14042942 | HUMANIZED ANTIBODIES SPECIFIC TO THE PROTOFIBRILLAR FORM OF THE BETA-AMYLOID PEPTIDE | October 2013 | February 2016 | Allow | 29 | 2 | 0 | No | Yes |
| 13949947 | PYRO-GLUTAMATE ABETA TARGETING AGENTS | July 2013 | April 2015 | Allow | 20 | 0 | 0 | Yes | No |
| 13903081 | ANITBODIES SPECIFIC FOR THE PROTOFIBRIL FORM OF BETA-AMYLOID PROTEIN | May 2013 | March 2016 | Allow | 33 | 2 | 1 | Yes | No |
| 13814568 | Methods and Compositions for the Inhibition of Fructokinase | May 2013 | February 2016 | Allow | 37 | 2 | 1 | Yes | No |
| 13881387 | Diagnosis and Treatment of Alzheimer's Disease | April 2013 | August 2014 | Allow | 15 | 1 | 1 | Yes | No |
| 13758754 | SPINAL MUSCULAR ATROPHY DIAGNOSTIC METHODS | February 2013 | October 2014 | Allow | 20 | 2 | 0 | Yes | No |
| 13667723 | HUMANIZED ANTIBODIES AGAINST THE BETA-AMYLOID PEPTIDE | November 2012 | October 2015 | Allow | 36 | 1 | 1 | Yes | No |
| 13591755 | POLYNUCLEOTIDES ENCODING HUMANIZED ANTI-FACTOR D ANTIBODIES | August 2012 | June 2013 | Allow | 10 | 0 | 1 | Yes | No |
| 13481087 | METHOD FOR TREATING PERVASIVE DEVELOPMENT DISORDERS | May 2012 | May 2013 | Allow | 12 | 1 | 0 | Yes | No |
| 13448061 | Method for Treating Pervasive Development Disorders | April 2012 | June 2014 | Allow | 26 | 2 | 1 | Yes | No |
| 13431893 | METHODS FOR TREATING DEPRESSION USING NCAM PEPTIDE MIMETICS | March 2012 | September 2015 | Allow | 41 | 3 | 0 | No | No |
| 13313629 | METHOD FOR TREATING PERVASIVE DEVELOPMENT DISORDERS | December 2011 | December 2016 | Allow | 60 | 4 | 0 | Yes | No |
| 13313708 | METHOD FOR TREATING PERVASIVE DEVELOPMENT DISORDERS | December 2011 | December 2016 | Allow | 60 | 4 | 0 | Yes | No |
| 13305025 | DOPAMINERGIC NEURONAL SURVIVAL-PROMOTING FACTORS AND USES THEREOF | November 2011 | March 2015 | Allow | 40 | 2 | 1 | Yes | No |
| 13266545 | PYRO-GLUTAMATE A BETA TARGETING AGENTS | October 2011 | April 2013 | Allow | 18 | 1 | 1 | Yes | No |
| 13188458 | METHODS AND COMPOSITIONS FOR TARGETING AGENTS INTO AND ACROSS THE BLOOD-BRAIN BARRIER AND OTHER ENDOTHELIAL CELL MICROVASCULAR BARRIERS | July 2011 | June 2013 | Allow | 23 | 2 | 0 | Yes | Yes |
| 13129579 | COMPOSITION FOR PRODUCING ANTI-AMYLOID BETA PEPTIDE ANTIBODIES WITH D-PEPTIDES | May 2011 | April 2015 | Allow | 47 | 4 | 1 | Yes | No |
| 13002174 | VACCINE AGAINST AMYLOID FOLDING INTERMEDIATE | March 2011 | January 2015 | Allow | 49 | 3 | 1 | Yes | No |
| 12985917 | COLLAGEN-LIKE PROTEIN CLAC, A PRECURSOR THEREOF, AND GENES ENCODING THE SAME | January 2011 | December 2011 | Allow | 12 | 1 | 1 | Yes | No |
| 12997673 | COMPOUNDS FOR TREATING AMYLOIDOSES | December 2010 | December 2012 | Allow | 24 | 2 | 1 | Yes | No |
| 12997674 | COMPOUNDS FOR TREATING BETA-AMYLOIDOSES | December 2010 | July 2013 | Allow | 31 | 2 | 1 | No | No |
| 12740217 | ANTIBODIES SPECIFIC OF THE BETA-AMYLOID PEPTIDES AND THEIR USES AS DIAGNOSTIC AGENTS OR DRUGS | November 2010 | August 2012 | Allow | 28 | 1 | 1 | Yes | No |
| 11920167 | METHOD FOR DIAGNOSING ALZHEIMER'S DISEASE USING SERUM GLYCOPROTEIN AS BIOMARKER | November 2010 | July 2013 | Allow | 60 | 3 | 0 | No | No |
| 12812712 | VACCINE FOR ALZHEIMER'S DISEASE | November 2010 | January 2016 | Allow | 60 | 4 | 1 | Yes | Yes |
| 12905930 | TREATMENT OF NEUROPATHIC PAIN USING ANTI-THROMBOSPONDIN ANTIBODIES | October 2010 | March 2013 | Allow | 29 | 1 | 1 | No | No |
| 12872645 | PCSK9 VACCINE | August 2010 | July 2014 | Allow | 46 | 2 | 1 | Yes | No |
| 12681050 | THERAPEUTIC ANTIBODY PURIFICATION METHOD AND METHOD OF USE | July 2010 | February 2013 | Allow | 35 | 2 | 0 | Yes | No |
| 12809563 | ANTI-AMYLOID ANTIBODIES AND USES THEREOF | June 2010 | December 2012 | Allow | 30 | 1 | 1 | Yes | No |
| 12677732 | HUMANIZED ANTIBODIES AGAINST THE BETA-AMYLOID PEPTIDE | June 2010 | July 2012 | Allow | 29 | 1 | 1 | Yes | No |
| 12792064 | HUMAN ANTI-AMYLOID BETA PEPTIDE ANTIBODY AND FRAGMENT OF SAID ANTIBODY | June 2010 | April 2012 | Allow | 22 | 0 | 0 | Yes | No |
| 12781962 | USE OF BIOLOGICAL PHOTORECEPTORS AS DIRECTLY LIGHT-ACTIVATED ION CHANNELS | May 2010 | February 2012 | Allow | 21 | 1 | 0 | Yes | No |
| 12297636 | TREATMENT OF AMYLOIDOGENIC DISEASES | May 2010 | May 2012 | Abandon | 43 | 1 | 2 | Yes | No |
| 12739599 | MONOCLONAL ANTIBODY FOR APP | April 2010 | September 2012 | Allow | 29 | 2 | 1 | Yes | No |
| 12738955 | ANTIBODIES SPECIFIC FOR THE PROTOFIBRIL FORM OF BETA-AMYLOID PROTEIN | April 2010 | April 2013 | Allow | 36 | 1 | 1 | Yes | No |
| 12514738 | AMYLOID-BETA BINDING PEPTIDES | March 2010 | March 2013 | Allow | 46 | 2 | 1 | Yes | No |
| 12608869 | Hybrid Amyloid-Beta Antibodies | October 2009 | February 2015 | Allow | 60 | 3 | 1 | No | Yes |
| 12444340 | METHOD OF DIAGNOSING NEUROPSYCHIATRIC DISEASES, EATING DISORDERS OR METABOLIC DISEASES | August 2009 | April 2012 | Allow | 37 | 2 | 1 | No | No |
| 12535029 | DOPAMINERGIC NEURONAL SURVIVAL-PROMOTING FACTORS AND USES THEREOF | August 2009 | September 2011 | Allow | 26 | 1 | 0 | No | No |
| 12500472 | COMPOSITION COMPRISING ANTIBODIES TO LINGO OR FRAGMENTS THEREOF | July 2009 | August 2011 | Allow | 26 | 1 | 1 | Yes | No |
| 12521309 | PEGYLATED ABETA FAB | June 2009 | July 2011 | Allow | 24 | 1 | 0 | Yes | No |
| 12487864 | METHOD FOR IDENTIFYING INDIVIDUALS HAVING A PERVASIVE DEVELOPMENT DISORDER AMENABLE TO DIGESTIVE ENZYME THERAPY | June 2009 | March 2012 | Allow | 33 | 2 | 1 | Yes | No |
| 12455324 | RBP4 IN INSULIN SENSITIVITY/RESISTANCE, DIABETES, AND OBESITY | June 2009 | March 2012 | Allow | 33 | 1 | 1 | Yes | No |
| 12430479 | HUMANIZED ANTI-FACTOR D ANTIBODIES AND USES THEREOF | April 2009 | May 2012 | Allow | 37 | 1 | 1 | Yes | No |
| 12339841 | AMYLOID-BETA POLYPEPTIDE VACCINE | December 2008 | July 2014 | Allow | 60 | 3 | 1 | Yes | No |
| 12330541 | HUMANIZED ANTI-BETA-AMYLOID ANTIBODIES | December 2008 | December 2013 | Allow | 60 | 2 | 1 | No | No |
| 12274793 | HUMANIZED PAI-1 ANTIBODIES | November 2008 | March 2011 | Allow | 27 | 1 | 1 | Yes | No |
| 12064190 | GDNF DERIVED PEPTIDES | November 2008 | November 2011 | Allow | 45 | 2 | 1 | Yes | No |
| 12238415 | METHOD FOR IDENTIFYING AUTISTIC INDIVIDUALS AMENABLE TO DIGESTIVE ENZYME THERAPY | September 2008 | June 2011 | Allow | 33 | 1 | 0 | Yes | No |
| 12283090 | METHOD FOR TREATING PERVASIVE DEVELOPMENT DISORDERS | September 2008 | September 2011 | Allow | 36 | 2 | 1 | Yes | No |
| 12205760 | HUMANIZED PAI-1 ANTIBODIES | September 2008 | March 2010 | Allow | 18 | 0 | 1 | Yes | No |
| 12280535 | PEPTIDE VACCINE FOR INDUCING THE PRODUCTION OF ANTI-AMYLOID ß-PEPTIDE ANTIBODY | August 2008 | June 2011 | Allow | 33 | 1 | 1 | Yes | No |
| 12189946 | ANTI-P55 TNF RECEPTOR ANTIBODY | August 2008 | February 2010 | Allow | 18 | 1 | 0 | Yes | No |
| 12189367 | IVIG MODULATION OF CHEMOKINES FOR TREATMENT OF MULTIPLE SCLEROSIS, ALZHEIMER'S DISEASE, AND PARKINSON'S DISEASE | August 2008 | November 2010 | Allow | 27 | 2 | 1 | Yes | No |
| 11664345 | ANTIBODIES DIRECTED TO THE MAMMALIAN EAG1 ION CHANNEL PROTEIN | June 2008 | October 2010 | Allow | 43 | 1 | 1 | Yes | No |
| 12046252 | METHODS OF TREATING AND DIAGNOSING PARKINSON'S DISEASE AND RELATED DYSAUTONOMIC DISORDERS | March 2008 | April 2014 | Allow | 60 | 3 | 0 | Yes | No |
| 12046402 | METHODS OF TREATING PERVASIVE DEVELOPMENT DISORDERS | March 2008 | April 2011 | Allow | 37 | 1 | 0 | Yes | No |
| 11997872 | METHODS FOR DETECTING PANCREATIC BETA-ISLET CELLS AND DISEASES THEREOF | March 2008 | October 2010 | Allow | 32 | 2 | 1 | Yes | No |
| 11576506 | COMPOSITIONS COMPRISING RECEPTOR-ASSOCIATED PROTEIN (RAP) VARIANTS SPECIFIC FOR LRP2 AND USES THEREOF | January 2008 | May 2014 | Allow | 60 | 4 | 1 | Yes | No |
| 11576502 | Compositions Comprising Receptor-Associated Protein (RAP) Variants Specific for CR-Containing Proteins and Uses Thereof | January 2008 | February 2015 | Allow | 60 | 4 | 1 | No | No |
| 11922482 | ANTIBODY HAVING INHIBITORY EFFECT ON AMYLOID FIBRIL FORMATION | December 2007 | January 2010 | Allow | 25 | 1 | 1 | Yes | No |
| 11958632 | REDUCING MYELIN-MEDIATED INHIBITION OF AXON REGENERATION | December 2007 | January 2010 | Allow | 25 | 1 | 1 | No | No |
| 11919897 | PEPTIDE CONJUGATE COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF ALZHEIMER'S DISEASE | November 2007 | August 2010 | Allow | 60 | 2 | 1 | Yes | No |
| 11931784 | POLYNUCLEOTIDE AND PROTEIN INVOLVED IN SYNAPTOGENESIS, VARIANTS THEREOF, AND THEIR THERAPEUTIC AND DIAGNOSTIC USES | October 2007 | August 2010 | Allow | 34 | 1 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner BALLARD, KIMBERLY.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 20.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner BALLARD, KIMBERLY works in Art Unit 1675 and has examined 132 patent applications in our dataset. With an allowance rate of 91.7%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 37 months.
Examiner BALLARD, KIMBERLY's allowance rate of 91.7% places them in the 76% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.
On average, applications examined by BALLARD, KIMBERLY receive 1.93 office actions before reaching final disposition. This places the examiner in the 47% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by BALLARD, KIMBERLY is 37 months. This places the examiner in the 32% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +14.3% benefit to allowance rate for applications examined by BALLARD, KIMBERLY. This interview benefit is in the 53% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 27.4% of applications are subsequently allowed. This success rate is in the 48% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 46.2% of cases where such amendments are filed. This entry rate is in the 70% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 87% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 87.5% are granted (fully or in part). This grant rate is in the 87% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 21.2% of allowed cases (in the 98% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.7% of allowed cases (in the 66% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.